In the pharmaceutical world, price hikes have been the gifts that keep on giving because the hefty cumulative effects of rising price tags greatly help year-over-year revenue growth. But a new analysis suggests the trend will slow considerably as drug makers face political pressure over pricing practices.

To wit, the compounded effect of rising prices contributed, on average, 5 percent in revenue growth annually over the last five years. Although total revenue growth slowed over the past year to around 1 percent, without price increases, the sales growth would have declined by a notable 6 percent, according to Leerink analyst Geoffrey Porges, who analyzed data for 17 large drug makers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Further confirmation of how dependent pharma has become on price increases — rather than new-therapy launches and/or market expansion for existing therapies — as their main engine of “sales growth.” I’ve often observed that this is rather like driving an out-of-gas car by repeatedly engaging the starter motor while in gear. For a while, it will create forward (if somewhat lurching) motion, but ultimately it will burn out the motor.

  • Xarelto pharmaceutical needs stopped and recalled due to there bleeding problem And J&j needs to settle out of court settlement agreement for the people’s pain and suffering from severe bleeding due to this medication

  • Ed,
    I wonder when the Feds are gonna address or if they’re gonna address the
    PBM issue. How many more states have to be robbed of millions before they see
    the light ?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy